- Home
- EDAP vs HLVX Comparison
EDAP vs HLVX Comparison
Compare EDAP & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDAP
- HLVX
- Stock Information
- Founded
- EDAP 1979
- HLVX 2020
- Country
- EDAP France
- HLVX United States
- Employees
- EDAP N/A
- HLVX N/A
- Industry
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- EDAP Health Care
- HLVX Health Care
- Exchange
- EDAP Nasdaq
- HLVX Nasdaq
- Market Cap
- EDAP 81.6M
- HLVX 87.6M
- IPO Year
- EDAP 1997
- HLVX 2022
- Fundamental
- Price
- EDAP $2.36
- HLVX $1.90
- Analyst Decision
- EDAP Strong Buy
- HLVX Hold
- Analyst Count
- EDAP 1
- HLVX 5
- Target Price
- EDAP $19.00
- HLVX $2.33
- AVG Volume (30 Days)
- EDAP 230.9K
- HLVX 245.3K
- Earning Date
- EDAP 11-07-2024
- HLVX 11-07-2024
- Dividend Yield
- EDAP N/A
- HLVX N/A
- EPS Growth
- EDAP N/A
- HLVX N/A
- EPS
- EDAP N/A
- HLVX N/A
- Revenue
- EDAP $70,722,730.00
- HLVX N/A
- Revenue This Year
- EDAP $6.96
- HLVX N/A
- Revenue Next Year
- EDAP $15.53
- HLVX N/A
- P/E Ratio
- EDAP N/A
- HLVX N/A
- Revenue Growth
- EDAP 12.17
- HLVX N/A
- 52 Week Low
- EDAP $2.14
- HLVX $1.55
- 52 Week High
- EDAP $8.50
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- EDAP 45.48
- HLVX 47.67
- Support Level
- EDAP $2.14
- HLVX $1.88
- Resistance Level
- EDAP $2.47
- HLVX $2.13
- Average True Range (ATR)
- EDAP 0.15
- HLVX 0.07
- MACD
- EDAP 0.02
- HLVX -0.01
- Stochastic Oscillator
- EDAP 33.96
- HLVX 15.56
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.